Months after they raked up the issue of mislabelling of baby oils, the Maharashtra Food & Drug Administration (FDA) seems to making some headway with one of the companies, Wipro, changing its label to accommodate regulatory concerns.
Kumar Chander, VP, marketing, Wipro Consumer Care, told ET that the company has incorporated a change in the label. “The FDA had concerns that the product should not be used wrongly on babies so we have incorporated a message indicating the recommended usage,” said Mr Chander.
Mr Chander said the product has not been rebranded and will continue to be called Wipro Baby Soft Oil. “We have said that the product can be used as a light application before bath,” he said.
Meanwhile, Johnson & Johnson, the major player in this market, is still waiting for feedback from the FDA. The company told ET that it has complied with the order passed by the FDA on May 5. “The order directed the company to submit the required information to the Drug Controller General of India and the FDA, which has been done.
The company is awaiting feedback on the information submitted,” J&J said. FDA commissioner M Ramesh Kumar told ET that the FDA had given the baby oil manufacturers certain directives and that the manufacturers have written back. “We are examining the responses and a final decision will be taken soon,” he said.
Wipro said the FDA has given it a statement saying the show-cause notice has been dropped.